COLchicine Versus Ruxolitinib and Secukinumab In Open Prospective Randomized Trial

COLchicine Versus Ruxolitinib and Secukinumab In Open Prospective Randomized Trial

Publication date: May 27, 2020

Patients with mild and severe coronavirus disease 2019 (COVID 19) will be randomized 3:1:1:3 into four groups: colchicine, ruxolitinib, secukinumab, and control groups. Patients will get investigated therapy for 10 days. Patients will be follow-up during 45 days after randomization. Change in clinical assessment score COVID 19 (CAS COVID 19) between baseline and 12th day will be evaluated as the primary endpoint. Risk of death or mechanical ventilation during 45 days after randomization will also be assessed

Concepts Keywords
Breastfeeding Colchicine
Colchicine Acetamides
Computer Tomography Alkaloids
Coronavirus RTT
Corticosteroids Drugs
Glomerular Filtration Rate Organic compounds
Hypersensitivity Chemical compounds
ICD 10 Mechanical ventilation
Immunosuppressive Therapy Immunosuppressive therapy
Liver Failure Virus pneumonia
Lomonosov Pyrazoles
Mechanical Ventilation Ruxolitinib
Moscow Secukinumab
Oxygen Randomized experiment
PCR Tomography
Pneumonia
Polymerase Chain Reaction
Pregnancy
Primary Endpoint
Randomization
Versus
Virus

Semantics

Type Source Name
drug DRUGBANK Colchicine
drug DRUGBANK Ruxolitinib
drug DRUGBANK Secukinumab
disease MESH death
disease MESH diagnosis
disease MESH pneumonia
drug DRUGBANK Oxygen
disease MESH hypersensitivity
disease MESH liver failure
disease MESH cancer

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *